Afrezza denied for missing prior authorization by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Afrezza

Humana requires prior authorization (PA) for Afrezza (inhaled insulin) because the drug is a branded, non-generic product in a therapeutic area where lower-cost injectable insulins are available and considered standard of care by most formulary committees. The PA requirement is a utilization-management gate — it is not an automatic denial, but an administrative checkpoint that requires the prescriber to demonstrate that Afrezza is appropriate for the specific patient before Humana will approve coverage.

Most prior-auth denials for Afrezza occur because the PA request was submitted with insufficient clinical documentation, because mandatory step-therapy requirements were not addressed, or because the request did not directly answer each criterion in Humana's PA criteria for this drug.

## Why a Denial After PA Submission Is Appealable

If Humana denies the PA request, that denial triggers your full appeal rights. Under ACA Section 2719 you are entitled to a complete internal appeal and then independent external review by a federally accredited IRO. ERISA Section 503 applies to self-funded plans and guarantees a full-and-fair review with disclosure of the specific criteria used. The external-review window is typically around four months from the final internal denial; expedited review (commonly 72 hours) is available when standard timelines would jeopardize health.

## How to Build a Strong PA Submission — or Appeal

1. Obtain Humana's current PA criteria for Afrezza before submitting. Request the clinical criteria document from Humana's provider portal or by calling Provider Services. Read every criterion and ensure the PA submission answers each one explicitly.

2. Document the diagnosis and clinical severity from the chart. Include recent relevant lab work, glucose monitoring records, and a summary of the patient's diabetes management history. The record should show the clinical picture clearly.

3. Address step-therapy requirements proactively. Humana's PA criteria almost certainly require documentation of prior use of covered insulin formulations. For each formulation tried, record the name, dates of use, doses or regimens attempted, and the specific clinical outcome that made it inadequate (e.g., documented hypoglycemia episodes, injection-site complications, comorbid conditions affecting injectable use).

4. Confirm FDA label eligibility and document it. The FDA-approved prescribing information for Afrezza defines the eligible patient population. Confirm with the prescriber that the patient meets every criterion in the label and that this is reflected in the chart.

5. Submit a prescriber medical-necessity letter. The letter must be individualized — not a form letter — and must address each PA criterion by name, citing specific chart data. Generic letters are routinely denied.

6. On appeal, request the specific denial rationale. Humana must tell you which criterion was not met. Build the appeal record around exactly that gap.

## Timeline

• PA decision: Typically within a few business days of submission; urgent requests may qualify for expedited processing.
• Internal appeal of PA denial: File within the period stated on the denial (often 180 days). Standard review typically 30 days; urgent/expedited 72 hours.
• External review: Available after final internal denial; request within approximately four months.

## Key Documents

• Humana's PA criteria for Afrezza (request current version)
• FDA prescribing label for Afrezza
• Complete insulin trial history with dates, outcomes, and prescriber notes
• Recent lab and monitoring records
• Individualized prescriber medical-necessity letter addressing each PA criterion
• Chart notes confirming diagnosis, severity, and clinical course